 
 
GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                                                                Synonyms: GSK-2636771
                                 Compound class: 
                                                            Synthetic organic
                                 
                                    
                                        Comment: GSK2636771 is a potent, orally bioavailable, PI3Kβ-selective inhibitor, with anticancer effects in PTEN null cells [2].
                                    
                                 | 
 | |||||||||||||||||||||||||||||||||||
| No information available. | 
| Summary of Clinical Use  | 
| GSK2636771 has progressed to Phase 2 clinical trial (October 2018). Click here to link to ClinicalTrials.gov's full list of GSK2636771 trials. |